Zipcode Bio
Zipcode Bio develops targeted nucleic acid therapeutics to address unmet medical needs. They leverage SHARP™, a single-component amphiphilic delivery platform that directs nucleic acids to the spleen and lungs. The approach offers advantages over traditional lipid nanoparticles, including easier production, improved efficacy, and better safety. The company combines RNA biology with machine learning tools, with research published in Nature Machine Intelligence, to optimize therapeutic design and pipelines for mRNA vaccines and lung diseases. With collaborations across universities and industry, Zipcode Bio aims to scale its platform and expand its portfolio.
Zipcode Bio
Zipcode Bio develops targeted nucleic acid therapeutics to address unmet medical needs. They leverage SHARP™, a single-component amphiphilic delivery platform that directs nucleic acids to the spleen and lungs. The approach offers advantages over traditional lipid nanoparticles, including easier production, improved efficacy, and better safety. The company combines RNA biology with machine learning tools, with research published in Nature Machine Intelligence, to optimize therapeutic design and pipelines for mRNA vaccines and lung diseases. With collaborations across universities and industry, Zipcode Bio aims to scale its platform and expand its portfolio.